Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Genetic Signatures Ltd

Healthcare AU GSS

0.074AUD
0.003(4.23%)

Last update at 2026-06-12T06:10:00Z

Day Range

0.070.07
LowHigh

52 Week Range

0.070.43
LowHigh

Fundamentals

  • Previous Close 0.07
  • Market Cap16.47M
  • Volume60166
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-10.42000M
  • Revenue TTM19.93M
  • Revenue Per Share TTM0.09
  • Gross Profit TTM 10.12M
  • Diluted EPS TTM-0.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -20.10400M -21.85400M -14.05200M 3.06M 1.76M
Minority interest - - - - -
Net income -20.10400M -17.86200M -14.05200M 3.06M 1.76M
Selling general administrative 16.07M 15.14M 15.04M 11.47M 10.02M
Selling and marketing expenses - - 1.28M 1.52M 1.32M
Gross profit 7.78M 4.31M 13.36M 23.43M 18.48M
Reconciled depreciation 2.40M 2.00M 1.53M 1.62M 1.43M
Ebit -18.48100M -21.81900M -14.05100M 3.08M 1.79M
Ebitda -16.07700M -19.82400M -12.52500M 4.70M 3.22M
Depreciation and amortization 2.40M 2.00M 1.53M 1.62M 1.43M
Non operating income net other - - - - -
Operating income -18.48100M -22.33300M -14.62200M 3.03M 1.53M
Other operating expenses 34.38M 30.39M 12.29M 5.35M 4.30M
Interest expense 0.09M 0.04M 0.00100M 0.02M 0.04M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 1.61M 0.50M 0.12M 0.13M 0.21M
Net interest income 1.52M 0.47M 0.54M 0.11M 0.17M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -3.85200M -3.99200M 0.15M 0.10M 0.27M
Total revenue 15.90M 9.77M 21.36M 35.42M 28.28M
Total operating expenses 26.26M 26.64M 28.11M 20.57M 17.12M
Cost of revenue 8.12M 5.46M 8.00M 11.99M 9.80M
Total other income expense net -1.62300M 0.48M 0.15M 0.09M 0.23M
Discontinued operations - - - - -
Net income from continuing ops -20.10400M -17.86200M -14.05200M 3.06M 1.76M
Net income applicable to common shares -20.10400M -17.86200M -14.05200M 3.06M 1.76M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 54.63M 67.29M 49.08M 59.65M 54.05M
Intangible assets - - 5.49M 1.65M 0.37M
Earning assets - - - - -
Other current assets 4.24M - 6.88M 6.88M -
Total liab 4.54M 6.18M 6.16M 4.85M 4.71M
Total stockholder equity 50.09M 61.10M 42.91M 54.80M 49.34M
Deferred long term liab - - - - -
Other current liab 0.84M 1.78M 2.30M 1.39M 1.87M
Common stock 127.64M 119.43M 84.44M 84.43M 84.16M
Capital stock 127.64M - 84.44M 84.43M 84.16M
Retained earnings -87.11300M -67.00900M -49.14700M -35.09500M -38.15800M
Other liab - - 0.10M 0.05M 0.02M
Good will - - - - -
Other assets - - - - -
Cash 7.47M 36.25M 16.35M 36.90M 30.12M
Cash and equivalents - - - - -
Total current liabilities 4.10M 5.23M 6.07M 4.80M 4.62M
Current deferred revenue - - - -0.03300M -0.33400M
Net debt -6.68200M -35.03100M -16.34900M -36.86300M -29.72200M
Short term debt 0.88M 0.39M 0.00000M 0.03M 0.33M
Short long term debt - - - - -
Short long term debt total 0.79M 1.22M - 0.03M 0.40M
Other stockholder equity - - -35.29100M -49.33300M -46.00600M
Property plant equipment - - 7.22M 6.78M 6.05M
Total current assets 47.98M 52.55M 36.37M 51.23M 47.63M
Long term investments - - - - -
Net tangible assets - - 37.42M 53.16M 48.97M
Short term investments 23.82M - 10.00M 25.00M 25.00M
Net receivables 3.38M 9.58M 4.39M 4.13M 5.37M
Long term debt - - - - -
Inventory 9.06M 6.72M 8.75M 10.20M 12.13M
Accounts payable 2.38M 3.06M 3.77M 3.42M 2.75M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 9.56M 8.68M 7.62M 5.47M 3.33M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 6.25M -12.71300M -8.42200M -6.41900M
Deferred long term asset charges - - - - -
Non current assets total 6.66M 14.73M 12.71M 8.42M 6.42M
Capital lease obligations 0.79M - - 0.03M 0.40M
Long term debt total - - 0.00000M 0.00100M 0.07M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -24.30200M -4.79100M -8.09400M -2.98900M -4.97900M
Change to liabilities - - 0.51M 0.31M 0.98M
Total cashflows from investing activities -24.30200M -4.79100M -8.09400M -2.98900M -4.97900M
Net borrowings - - -0.03300M -0.36500M -0.34100M
Total cash from financing activities 7.79M 34.81M -0.02300M -0.10100M -0.19000M
Change to operating activities - - -4.21400M 0.20M 2.83M
Net income -20.10400M -17.86200M -14.05200M 3.06M 1.76M
Change in cash -28.77900M 19.90M -20.54800M 6.78M -1.05500M
Begin period cash flow 36.25M 16.35M 36.90M 30.12M 31.18M
End period cash flow 7.47M 36.25M 16.35M 36.90M 30.12M
Total cash from operating activities -12.28900M -10.12000M -12.45100M 9.81M 4.20M
Issuance of capital stock 8.77M 37.52M 0.01M 0.27M 0.16M
Depreciation - 2.00M 1.53M 1.62M 1.38M
Other cashflows from investing activities -0.24900M -2.81200M - - -
Dividends paid - - - - -
Change to inventory -2.74600M 1.62M 1.03M 1.93M -5.15200M
Change to account receivables 1.42M 2.71M 0.50M 1.24M -0.29300M
Sale purchase of stock -0.55400M -2.53000M -0.00100M -0.00900M -0.01200M
Other cashflows from financing activities -0.43000M -0.17700M -0.03300M -0.36500M -0.34100M
Change to netincome - - 2.26M 1.44M 2.64M
Capital expenditures 0.90M 4.79M 8.09M 2.99M 4.98M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -2.54800M 4.20M 1.52M 3.17M -5.44500M
Stock based compensation - - 1.97M 1.92M 1.48M
Other non cash items -9.74100M 1.55M 0.07M 5.13M 1.06M
Free cash flow -13.19100M -14.91100M -20.54500M 6.82M -0.78400M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
GSS
Genetic Signatures Ltd		 0.003 4.23% 0.07 - 52.36 0.83 0.37 0.15 -12.2935
SHL
Sonic Healthcare Ltd		 -0.08 0.39% 20.20 18.27 14.47 0.96 1.14 1.46 8.61
IDX
Integral Diagnostics Ltd		 0.01 0.49% 2.04 50.25 13.40 0.98 1.11 1.72 10.99
ACL
Australian Clinical Labs Ltd		 - -% 2.16 15.43 12.00 0.55 2.69 0.95 3.88
PEB
Pacific Edge Ltd		 0.01 4.00% 0.26 - - 22.52 33.42 30.52 -7.8581

Reports Covered

Stock Research & News

View All

Profile

Genetic Signatures Limited operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas. It offers enteric bacteria, Enteroaggregative E.coli aggR and aaiC, enteric viral, enteric protozoan, enteric protozoan extended, enteric microsporidia, respiratory pathogen, SARS-CoV-2, extended respiratory, atypical respiratory, Measles, Mumps, and Rubella detection kits under the EasyScreen name. The company was incorporated in 2001 and is headquartered in Newtown, Australia.

Genetic Signatures Ltd

Heart Research Institute, Newtown, NSW, Australia, 2042

Key Executives

Name Title Year Born
Dr. John R. Melki BSc, Ph.D. MD, CEO & Exec. Director NA
Mr. Peter L. Manley CPA CFO & Company Sec. NA
Mr. Michael Anton Aicher BSc, M.B.A., MBA Exec. Director of US Operations & Exec. Director 1960
Mr. Christopher M. Abbott Founder & Chairman Emeritus NA
Dr. Douglas S. Millar BSc, Ph.D. Chief Scientific Officer NA
Ms. Neralie Coulston B.Sc. Global Head of Regulatory Affairs NA
Mr. Jackson Jones B.Sc. Chief Commercial Officer NA
Dr. John R. Melki BSc, Ph.D. MD, CEO & Executive Director NA
Mr. Michael Anton Aicher BSc, M.B.A., MBA Executive Director of US Operations & Executive Director 1960
Mr. Karl David Pechmann CFO, COO & Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.